Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27306328 | 0.88 | SLC22A6 (0.35) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL28006567 | 0.87 | SLC22A6 (0.38) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL27464365 | 0.87 | SLC22A6 (0.38) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL7832375 | 0.86 | SLC22A6 (0.33) | SLC22A6TDP1SMN1; SMN2 | |
| SCHEMBL1604218 | 0.85 | SLC22A6 (0.36) | SLC22A6TDP1SMN1; SMN2GABRR1CACNA2D1 | |
| SCHEMBL28474842 | 0.85 | GABRR1 (0.46) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL27823940 | 0.83 | DPP4 (0.37) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL499817 | 0.81 | GPR84 (0.39) | SLC22A6TDP1TSHRCACNA2D1CACNB3 | |
| SCHEMBL27824024 | 0.81 | TSHR (0.38) | SLC22A6TDP1SMN1; SMN2TSHRFOLH1 | |
| SCHEMBL27383612 | 0.79 | GAA (0.40) | TDP1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113997650-A | Multilayer structure assembly with force-induced responsiveness | 厦门天策材料科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113978071-A | Multilayer structure assembly | 翁秋梅 | 2022-01-28 | — | — | CN | disclosed |
| CN-111378142-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378145-A | Force-induced response multiphase supramolecular block polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111378179-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| CN-111134409-A | Self-adaptive clothes | 翁秋梅 | 2020-05-12 | — | — | CN | disclosed |
| CN-104470895-B | The purposes of N [3 (2 carboxy ethyl) phenyl] piperidinyl-1 yl acetamide derivatives and its activator as soluble guanylate cyclase | 拜耳制药股份公司 | 2017-04-05 | — | — | CN | disclosed |
| EP-2852573-B1 | N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9309198-B2 | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-5631209-A | ALGICIDES | ROHM AND HAAS COMPANY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5502027-A | ALGICIDES | ROHM AND HAAS COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0415642-B1 | Glutarimides | ROHM & HAAS (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5393735-A | N-(halo-oxy-)phenyl substituted cyclic imides | ROHM AND HAAS COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0415641-B1 | Substituted glutaramic acids and derivatives | ROHM & HAAS (US) | 1994-01-19 | — | — | EP | disclosed |
| US-5238908-A | HERBICIDAL GLUTARAMIC ACIDS AND DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| CN-1049770-A | Weeding glutaramic acid and its derivative | ROHM & HAAS (US) | 1991-03-13 | — | — | CN | disclosed |
| CN-1049846-A | Glutarimide with weeding activity | ROHM & HAAS (US) | 1991-03-13 | — | — | CN | disclosed |
| EP-0415641-A1 | Substituted glutaramic acids and derivatives | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0415642-A1 | Glutarimides | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | GUCY1A2, GUCY1A1, GUCY1B2 | SLC22A6 4002/4885TDP1 1468/4885SMN1; SMN2 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.